Gilead sciences, inc. GILD.US Overview
GILD AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
GILD Current Performance
-2.70%
Gilead sciences, inc.
-1.83%
Avg of Sector
-0.40%
S&P500
GILD Key Information
GILD Revenue by Segments
Browsing restrictions can be lifted for a fee.
GILD Net Income
Browsing restrictions can be lifted for a fee.
GILD Cash Flow
Browsing restrictions can be lifted for a fee.
GILD Profit Margin
Browsing restrictions can be lifted for a fee.
GILD PE Ratio River
Browsing restrictions can be lifted for a fee.
GILD Financial Forecast
Browsing restrictions can be lifted for a fee.
GILD Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
GILD Profile
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Price of GILD
GILD FAQ
When is GILD's latest earnings report released?
The most recent financial report for Gilead sciences, inc. (GILD) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating GILD's short-term business performance and financial health. For the latest updates on GILD's earnings releases, visit this page regularly.
Where does GILD fall in the P/E River chart?
According to historical valuation range analysis, Gilead sciences, inc. (GILD)'s current price-to-earnings (P/E) ratio is 20.62, placing it in the Value zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
What is the operating profit of GILD?
According to the latest financial report, Gilead sciences, inc. (GILD) reported an Operating Profit of 2.24B with an Operating Margin of 33.55% this period, representing a growth of 151.76% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is GILD's revenue growth?
In the latest financial report, Gilead sciences, inc. (GILD) announced revenue of 6.67B, with a Year-Over-Year growth rate of -0.28%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does GILD have?
As of the end of the reporting period, Gilead sciences, inc. (GILD) had total debt of 24.95B, with a debt ratio of 0.44. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does GILD have?
At the end of the period, Gilead sciences, inc. (GILD) held Total Cash and Cash Equivalents of 7.93B, accounting for 0.14 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does GILD go with three margins increasing?
In the latest report, Gilead sciences, inc. (GILD) achieved the “three margins increasing” benchmark, with a gross margin of 76.9%%, operating margin of 33.55%%, and net margin of 19.7%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess GILD's profit trajectory and future growth potential.
Is GILD's EPS continuing to grow?
According to the past four quarterly reports, Gilead sciences, inc. (GILD)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 1.06. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of GILD?
Gilead sciences, inc. (GILD)'s Free Cash Flow (FCF) for the period is 1.65B, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 21.81% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.